Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aquestive Therapeutics, Inc.AQST · Entity 5276 | Director | June 10, 2026 | June 12, 2026 |
| DBV Technologies S.A.DBVT · Entity 5096 | Director | August 25, 2023 | August 28, 2023 |
| HUMANIGEN, INCHGEN · Entity 108862 | COO and CFO | July 27, 2022 | July 29, 2022 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Chief Financial Officer | March 04, 2019 | March 06, 2019 |
| TALPHERA, INC.ACRX · Entity 7102 | Chief Financial Officer | February 07, 2017 | February 10, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aquestive Therapeutics, Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $3.99 · Expires 2036-06-10 | Direct | 50,500 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 50,500 · Balance 50,500 F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Mr. Morris' continuous service with the Issuer from the grant date through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Mr. Morris' continuous service with the Issuer from the grant date through the applicable vesting date.
DBV Technologies S.A.
Report date August 25, 2023 · Filed August 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 12,000 |
Reported balance
After 2023-08-25 transaction · row 1
1 source rowRow 1 · 2023-08-25 · Purchase · Acquired 12,000 · Balance 12,000 |
HUMANIGEN, INC
Report date July 27, 2022 · Filed July 29, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2032-07-26 | Direct | 600,360 |
Reported balance
After 2022-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-27 · Grant · Acquired 600,360 · Balance 600,360 F1: The stock option vests in two equal installments on the first and second anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in two equal installments on the first and second anniversaries of the grant date.
IOVANCE BIOTHERAPEUTICS, INC.
Report date March 04, 2019 · Filed March 06, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.26 · Expires 2019-03-04 | Direct | 100,000 |
Reported balance
After 2019-03-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-03-04 · Grant · Acquired 100,000 · Balance 100,000 F1: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 100,000 shares shall vest on the one-year anniversary of March 4, 2019; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of March 4, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 100,000 shares shall vest on the one-year anniversary of March 4, 2019; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of March 4, 2019.
TALPHERA, INC.
Report date February 07, 2017 · Filed February 10, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2028-02-06 | Direct | 112,500 |
Reported balance
After 2017-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-07 · Grant · Acquired 112,500 · Balance 112,500 F1: Issued pursuant to the 2011 Equity Incentive Plan. F2: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date (February 7, 2017) and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. F3: 100% Acceleration upon Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: Issued pursuant to the 2011 Equity Incentive Plan.
F2: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date (February 7, 2017) and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months.
F3: 100% Acceleration upon Change of Control.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2026 Filed Jun 12, 2026 11:43 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (right to purchase) · Derivative | 50,500 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001214659-26-007399 · marketforms-73385.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,500 Underlying: Common Stock · 50,500 shares Expires 2036-06-10 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Mr. Morris' continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 11, 2025 Filed Jun 12, 2025 13:59 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (right to purchase) · Derivative | 42,000 | $3.41 Strike: $3.41 | $143,220.00 |
DisclosureSEC source: 0001214659-25-009122 · marketforms-69483.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 11, 2026, subject to Mr. Morris' continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 13:51 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (right to purchase) · Derivative | 38,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001214659-24-011221 · marketforms-66328.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2034-06-20 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 25, 2025, subject to Mr. Morris' continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| August 25, 2023 Filed Aug 28, 2023 16:35 UTC | DBV Technologies S.A. DBVT · Entity 5096 | PurchaseOrdinary Shares | 12,000 | $1.52 | $18,240.00 |
DisclosureSEC source: 0001209191-23-047517 · doc4.xml · nonDerivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Read SEC document |
| June 21, 2023 Filed Jun 23, 2023 12:27 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantStock Option (right to purchase) · Derivative | 25,000 | $0.00 Strike: $2.02 | $0.00 |
DisclosureSEC source: 0001214659-23-008796 · marketforms-61963.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying the options vest as follows: 100% of the underlying shares vest June 21, 2024, subject to Mr. Morris' continuous service with the Issuer from the grant date through the applicable vesting date. Read SEC document |
| August 16, 2022 Filed Aug 17, 2022 15:35 UTC | Aquestive Therapeutics, Inc. AQST · Entity 5276 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 28,500 | $0.00 Strike: $1.50 | $0.00 |
DisclosureSEC source: 0001214659-22-010328 · marketforms-56912.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,500 Underlying: Common Stock · 28,500 shares Expires 2032-08-16 F1 · derivative.exercise_date: Granted under the Company's 2018 Equity Incentive Plan, which meets the requirements of Rule 16b-3. The options will vest in three annual installments with 1/3% on the 1st installment, 1/3% on the 2nd installment and 1/3% on the 3rd installment. Read SEC document |
| July 27, 2022 Filed Jul 29, 2022 18:30 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 600,360 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001214659-22-009385 · marketforms-56752.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600,360 Underlying: Common Stock · 600,360 shares Expires 2032-07-26 F1 · derivative.exercise_date: The stock option vests in two equal installments on the first and second anniversaries of the grant date. Read SEC document |
| January 12, 2022 Filed Jan 14, 2022 17:06 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 59,841 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0001214659-22-000735 · marketforms-55061.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,841 Underlying: Common Stock · 59,841 shares Expires 2032-01-11 F1 · price: The stock option was granted to the Reporting Person at the direction of the Company in satisfaction of amounts earned under the Company's 2021 annual incentive plan. Read SEC document |
| December 31, 2021 Filed Jan 4, 2022 18:20 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 51,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001214659-22-000265 · marketforms-54935.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,000 Underlying: Common Stock · 51,000 shares Expires 2031-12-30 F1 · derivative.exercise_date: The option vests in 12 ratable quarterly installments commencing March 31, 2022. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 16:54 UTC | DBV Technologies S.A. DBVT · Entity 5096 | PurchaseWarrant (right to buy) · Derivative | 6,837 | $7.12 Strike: $13.09 | $48,679.44 |
DisclosureSEC source: 0001209191-21-039886 · doc4.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,837 Underlying: Ordinary Shares · 6,837 shares Expires 2025-06-10 F1 · derivative.exercise_price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021. F1 · price: This price is in US Dollars and reflects the conversion of EUR to USD at an exchange rate of $1.2176 to EUR 1.00 as of June 10, 2021. Read SEC document |
| September 18, 2020 Filed Sep 22, 2020 17:37 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 151,316 | $0.00 Strike: $9.65 | $0.00 |
DisclosureSEC source: 0001214659-20-008051 · marketforms-49729.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,316 Underlying: Common Stock · 151,316 shares Expires 2030-09-18 F1 · derivative.exercise_date: The option vests in 12 ratable quarterly installments commencing December 31, 2020. Read SEC document |
| March 04, 2019 Filed Mar 6, 2019 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $11.26 | $0.00 |
DisclosureSEC source: 0001144204-19-012579 · tv515607_4.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common stock · 100,000 shares Expires 2019-03-04 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 100,000 shares shall vest on the one-year anniversary of March 4, 2019; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of March 4, 2019. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:54 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 88,235 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001214659-18-002135 · marketforms-41411.xml · derivative · entry 2 MORRIS TIMOTHY E · CIK 0001191286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,235 Underlying: Common Stock · 88,235 shares Expires 2028-03-08 F2 · derivative.exercise_date: These stock options were granted in lieu of 50% of the cash compensation payable to Mr. Morris in respect of his services as a director during 2017. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:54 UTC | HUMANIGEN, INC HGEN · Entity 108862 | GrantStock Option (Right to Buy) · Derivative | 715,877 | $0.00 Strike: $0.67 | $0.00 |
DisclosureSEC source: 0001214659-18-002135 · marketforms-41411.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 715,877 Underlying: Common Stock · 715,877 shares Expires 2028-03-08 F1 · derivative.exercise_date: The option vests in 12 ratable quarterly installments commencing June 30, 2018. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 18:12 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0001250853-17-000073 · primary_doc.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2027-08-13 F1 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of the 250,000 shares shall vest on the one-year anniversary of August 14, 2017; and (ii) the remaining options shall vest as to one-twelfth of 250,000 shares at the end of each quarter over the next two years, commencing with the first quarter following the first anniversary of August 14, 2017. Read SEC document |
| February 07, 2017 Filed Feb 10, 2017 01:57 UTC | TALPHERA, INC. ACRX · Entity 7102 | GrantCommon Stock (Right to Buy) · Derivative | 112,500 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001437749-17-002066 · rdgdoc.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2028-02-06 F1 · security: Issued pursuant to the 2011 Equity Incentive Plan. F2 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vest on the 12 month anniversary of the Vesting Commencement Date (February 7, 2017) and the remaining shares subject to the option vest on an equal monthly basis over the following 36 months. F3 · derivative.exercise_date: 100% Acceleration upon Change of Control. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 17:39 UTC | HUMANIGEN, INC KBIO · Entity 108862 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $3.38 | $0.00 |
DisclosureSEC source: 0001123292-16-002733 · edgar.xml · derivative · entry 1 MORRIS TIMOTHY E · CIK 0001191286 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2026-09-12 F1 · derivative.exercise_date: The option vests and becomes exercisable in 12 equal quarterly installments beginning on December 13, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.